Skip to Main Content

ABBVIE INC.

ABBV Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

$ABBV stock is featured in our Dan Meuser, Rob Bresnahan, and Tom Carper strategies.

All Strategies
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of ABBV by members of U.S. Congress

Politician Type Traded
Lisa C. McClain House / R Sale $1,001 - $15,000 Oct 31, 2025
Lisa C. McClain House / R Purchase $1,001 - $15,000 Oct 30, 2025
Lisa C. McClain House / R Sale $1,001 - $15,000 Oct 30, 2025
John Boozman Senate / R Sale (Partial) $1,001 - $15,000 Aug 22, 2025
Julie Johnson House / D Sale $1,001 - $15,000 Aug 14, 2025
John Boozman Senate / R Sale (Partial) $1,001 - $15,000 Aug 11, 2025
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 Aug 04, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 04, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Aug 04, 2025
Lisa C. McClain House / R Purchase $1,001 - $15,000 Jul 22, 2025
Lisa C. McClain House / R Sale $1,001 - $15,000 Jul 22, 2025
Ritchie Torres House / D Sale $1,001 - $15,000 Jul 11, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Jul 01, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Jul 01, 2025
Lisa C. McClain House / R Purchase $1,001 - $15,000 Jun 17, 2025
Ro Khanna House / D Purchase $15,001 - $50,000 May 28, 2025
Josh Gottheimer House / D Purchase $1,001 - $15,000 May 22, 2025
Robert Bresnahan House / R Purchase $1,001 - $15,000 May 15, 2025
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 May 05, 2025
Josh Gottheimer House / D Sale $1,001 - $15,000 Apr 17, 2025
Jefferson Shreve House / R Sale $50,001 - $100,000 Apr 17, 2025
Ro Khanna House / D Sale $15,001 - $50,000 Apr 09, 2025
Robert Bresnahan House / R Sale $1,001 - $15,000 Apr 08, 2025
Jared Moskowitz House / D Purchase $1,001 - $15,000 Apr 07, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Apr 04, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Apr 04, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Apr 04, 2025
Josh Gottheimer House / D Purchase $1,001 - $15,000 Apr 03, 2025
Dwight Evans House / D Sale $1,001 - $15,000 Apr 03, 2025
Josh Gottheimer House / D Purchase $1,001 - $15,000 Apr 01, 2025
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 Mar 17, 2025
Ro Khanna House / D Sale $1,001 - $15,000 N/A
Ro Khanna House / D Purchase $1,001 - $15,000 Mar 06, 2025
Robert Bresnahan House / R Purchase $1,001 - $15,000 Feb 25, 2025
Jefferson Shreve House / R Purchase $50,001 - $100,000 Feb 24, 2025
Ro Khanna House / D Purchase $15,001 - $50,000 Feb 19, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Feb 05, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Feb 05, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Feb 04, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Feb 04, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Feb 04, 2025
Ro Khanna House / D Purchase $1,001 - $15,000 Jan 22, 2025
Ro Khanna House / D Sale $1,001 - $15,000 Jan 17, 2025
Jared Moskowitz House / D Purchase $1,001 - $15,000 Jan 15, 2025
Jared Moskowitz House / D Purchase $1,001 - $15,000 Jan 15, 2025
Virginia Foxx House / R Purchase $1,001 - $15,000 Dec 06, 2024
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 Nov 20, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 14, 2024
Ritchie Torres House / D Purchase $1,001 - $15,000 Sep 26, 2024
John James House / R Sale $1,001 - $15,000 Sep 04, 2024
ABBV Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
ABBV Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
ABBV Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes in ABBV holdings by institutional investors

Quarterly net insider trading by ABBV's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

  • $980,000 Oct 20, 2025 Issue: Trade (domestic/foreign) Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace
  • $1,160,000 Jul 21, 2025 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace Trade (domestic/foreign)
  • $2,110,000 Apr 21, 2025 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace
  • $1,080,000 Jan 21, 2025 Issue: Copyright/Patent/Trademark Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Labor Issues/Antitrust/Workplace
  • $1,280,000 Oct 21, 2024 Issue: Labor Issues/Antitrust/Workplace Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $580,000 Jul 22, 2024 Issue: Labor Issues/Antitrust/Workplace Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $1,590,000 Apr 22, 2024 Issue: Labor Issues/Antitrust/Workplace Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $830,000 Jan 22, 2024 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $750,000 Oct 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $600,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $970,000 Jan 20, 2023 Issue: Budget/Appropriations Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $2,370,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $880,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $3,980,000 Apr 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Health Issues Copyright/Patent/Trademark
  • $1,290,000 Jan 20, 2022 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
  • $1,940,000 Oct 20, 2021 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
  • $680,000 Jul 20, 2021 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark
  • $3,090,000 Apr 20, 2021 Issue: Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Medicare/Medicaid Trade (domestic/foreign)
  • $650,000 Jan 20, 2021 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $1,430,000 Oct 20, 2020 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $670,000 Jul 20, 2020 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
  • $2,980,000 Apr 20, 2020 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $970,000 Jan 21, 2020 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Budget/Appropriations
  • $1,790,000 Oct 21, 2019 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark
  • $900,000 Jul 22, 2019 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $2,680,000 Apr 22, 2019 Issue: Medicare/Medicaid Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Health Issues
  • $1,820,000 Jan 22, 2019 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
  • $600,000 Oct 22, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code
  • $790,000 Jul 20, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $2,890,000 Apr 20, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $1,280,000 Jan 22, 2018 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Disaster Planning/Emergencies
  • $1,200,000 Oct 20, 2017 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $720,000 Jul 20, 2017 Issue: Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Copyright/Patent/Trademark Budget/Appropriations
  • $2,460,000 Apr 20, 2017 Issue: Medicare/Medicaid Health Issues Trade (domestic/foreign) Taxation/Internal Revenue Code Budget/Appropriations Copyright/Patent/Trademark
  • $1,040,000 Jan 20, 2017 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code
  • $2,610,000 Oct 28, 2016 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid Budget/Appropriations
  • $1,920,000 Oct 20, 2016 Issue: Budget/Appropriations Health Issues Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid
  • $1,700,000 Jul 20, 2016 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Budget/Appropriations
  • $1,180,000 Jan 20, 2016 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign)
  • $1,240,000 Oct 19, 2015 Issue: Health Issues Taxation/Internal Revenue Code Budget/Appropriations Medicare/Medicaid Copyright/Patent/Trademark Trade (domestic/foreign)
  • $930,000 Oct 19, 2015 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Copyright/Patent/Trademark Trade (domestic/foreign)
  • $1,870,000 Oct 19, 2015 Issue: Medicare/Medicaid Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Budget/Appropriations Trade (domestic/foreign)
  • $1,010,000 Jan 20, 2015 Issue: Budget/Appropriations Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid
  • $1,600,000 Oct 17, 2014 Issue: Health Issues Copyright/Patent/Trademark Taxation/Internal Revenue Code Medicare/Medicaid Budget/Appropriations Trade (domestic/foreign)
  • $880,000 Jul 21, 2014 Issue: Budget/Appropriations Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid Copyright/Patent/Trademark
  • $1,450,000 Apr 21, 2014 Issue: Budget/Appropriations Health Issues Medicare/Medicaid Trade (domestic/foreign) Taxation/Internal Revenue Code Copyright/Patent/Trademark
  • $600,000 Jan 21, 2014 Issue: Trade (domestic/foreign) Health Issues Medicare/Medicaid Budget/Appropriations Taxation/Internal Revenue Code Copyright/Patent/Trademark
  • $630,000 Oct 21, 2013 Issue: Science/Technology Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid Budget/Appropriations Health Issues
  • $1,180,000 Oct 21, 2013 Issue: Copyright/Patent/Trademark Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Budget/Appropriations Medicare/Medicaid
  • $770,000 Apr 22, 2013 Issue: Health Issues Budget/Appropriations Taxation/Internal Revenue Code Trade (domestic/foreign) Medicare/Medicaid

ABBV Estimated quarterly lobbying spending

ABBV Revenue by Segment or Geography

By Segment
By Geography
ABBV Income Statement
ABBV Balance Sheet
ABBV Cash Flow
U.S. Patents

New ABBV patent grants

  • Patent Title: Carrying vest Jul. 08, 2025
  • Patent Title: Infusion pump May. 20, 2025
  • Patent Title: Carrying vest Apr. 15, 2025
  • Patent Title: Container cap Mar. 11, 2025
  • Patent Title: Carrying pack for medical device Mar. 11, 2025
  • Patent Title: Container cap Jul. 09, 2024
  • Patent Title: Carrying pack Dec. 12, 2023
  • Patent Title: Crystal forms Feb. 08, 2022
  • Patent Title: Tricyclic compounds Feb. 05, 2019
  • Patent Title: Bromodomain inhibitors Jun. 12, 2018
  • Patent Title: Indole and indoline derivatives and methods of use thereof May. 29, 2018
  • Patent Title: Automatic injection device May. 29, 2018
  • Patent Title: Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography May. 22, 2018
  • Patent Title: 6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use May. 15, 2018
  • Patent Title: Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrol and solid state forms thereof May. 08, 2018
  • Patent Title: Protein purification methods to reduce acidic species May. 01, 2018
  • Patent Title: Indane inhibitors of eed and methods of their use May. 01, 2018
  • Patent Title: Bromodomain inhibitors May. 01, 2018
  • Patent Title: Shroud deployment in automatic injection devices May. 01, 2018
  • Patent Title: Wearable automatic injection device for controlled administration of therapeutic agents May. 01, 2018
  • Patent Title: Aβ conformer selective anti-aβ globulomer monoclonal antibodies Apr. 24, 2018
  • Patent Title: Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Apr. 24, 2018
  • Patent Title: Methods of adminstering elagolix Apr. 24, 2018
  • Patent Title: Acoustic mixing for auto granulation Apr. 24, 2018
  • Patent Title: Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof Apr. 17, 2018
  • Patent Title: Automatic injection device Apr. 17, 2018
  • Patent Title: Inhibitor compounds of phosphodiesterase type 10a Apr. 10, 2018
  • Patent Title: Substituted indoles Apr. 03, 2018
  • Patent Title: High-throughput system and method for identifying antibodies having specific antigen binding activities Mar. 13, 2018
  • Patent Title: Single-chain trail-receptor agonist proteins Mar. 06, 2018
  • Patent Title: Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Jan. 30, 2018
  • Patent Title: Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl and solid state forms thereof Jan. 30, 2018
  • Patent Title: Indazolones as modulators of tnf signaling Jan. 30, 2018
  • Patent Title: Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases Jan. 30, 2018
  • Patent Title: Salt and crystalline forms thereof of a drug Jan. 23, 2018
  • Patent Title: Methods of treatment using selective bcl-2 inhibitors Jan. 23, 2018
  • Patent Title: Carrying case for medical delivery device Jan. 17, 2017
  • Patent Title: Delivery device including pump and cassette Sep. 13, 2016
  • Patent Title: Connector Aug. 23, 2016
  • Patent Title: Connector Aug. 23, 2016
  • Patent Title: Garment with carrying case for medical delivery device Aug. 23, 2016
  • Patent Title: Injection tool Jul. 05, 2016
  • Patent Title: Template for a prescription medicine container Feb. 02, 2016
  • Patent Title: Template for a prescription medicine container Jan. 19, 2016
  • Patent Title: Template for a prescription medicine container Jan. 12, 2016
  • Patent Title: Interface portion of a pump Jan. 05, 2016
  • Patent Title: Pump Nov. 24, 2015
  • Patent Title: Template for a prescription medicine container Jun. 16, 2015
  • Patent Title: Template for a prescription medicine container Jun. 16, 2015
  • Patent Title: Template for a prescription medicine container Jun. 09, 2015
Government Contracts

Estimated quarterly amount awarded to ABBV from public contracts

ABBV News

Recent insights relating to ABBV

CNBC Recommendations

Recent picks made for ABBV stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ABBV

ABBV Analyst Ratings

ABBV Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
ABBV Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $ABBV stock a Buy, Sell, or Hold?

  • What is the price target for $ABBV stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

ABBV Top Shareholders
Shareholder
Shares Held
ABBV Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $ABBV stock?

  • Who owns the most shares of $ABBV stock?

  • What funds own $ABBV stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

ABBV Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view ABBV Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About ABBV

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

  • Address North Chicago, IL
  • Market Cap 417.6 billion
  • Employees 55,000
  • Industrial Classification Pharmaceutical Preparations
Back To Top